EISAI S.A. IN FRANCE ACQUIRES ALL SHARES OF BIODIM S.A.S.
Tokyo (February 21, 2002) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced that its subsidiary in France, Eisai S.A. (General Manager: Paul Cadre) has acquired the marketing rights of three central nervous systems drugs and two gastrointestinal treatment drugs through an agreement to purchase of all capital shares in BIODIM S.A.S. on February 18. The total cost of the acquisition is approximately 21 million. (about 2.4 billion)
BIODIM S.A.S. has three central nervous system products (Loxapac, Parkinane, and Defanyl) and two gastrointestinal products (Génésérine and Anti-H). These five products in 2000 had sales in France of approximately 8 million (about 0.9 billion). With the conclusion of this agreement, Eisai S.A. will market, including ARICEPT , a total of six products in the central nervous and gastrointestinal therapeutic areas.
In Europe Eisai established sales and marketing subsidiaries in the United Kingdom in 1995, in Germany and France in 1996, and a marketing subsidiary in Spain in 2001.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The Company reported sales of over $2.9 billion in 2000 with approximately 14 percent of sales spent for research and development.
ARICEPT is a registered trademark of Eisai Co., Ltd.
< BIODIM S.A.S. Company Outline (Prior to Agreement) >